Discontinuing Soliris Is Safe for Certain aHUS Patients

Discontinuing Soliris Is Safe for Certain aHUS Patients

307738

Discontinuing Soliris Is Safe for Certain aHUS Patients

Treatment with Soliris (eculizumab) may be discontinued with close monitoring in people with atypical hemolytic uremic syndrome (aHUS) whose disease is in remission for at least six months — providing their kidney function remains stable — or in those who have developed end-stage kidney disease, a small study suggests. The findings also indicated that patients with treatment-induced HUS are not likely to experience relapses after discontinuing Soliris therapy. “[Soliris] treatment has dramatically improved the outcomes…

You must be logged in to read/download the full post.